Clinically Relevant Cytotoxic Immune Cell Signatures and Clonal Expansion of T-Cell Receptors in High-Risk MYCN-Not-Amplified Human Neuroblastoma

Clin Cancer Res. Volume 24, Issue 22: p.5673–5684, 21 May 2018 10.1158/1078-0432.ccr-18-0599

Purpose: High-risk neuroblastoma is an aggressive disease. DNA sequencing studies have revealed a paucity of actionable genomic alterations and a low mutation burden, posing challenges to develop effective novel therapies. We used RNA sequencing (RNA-seq) to investigate the biology of this disease, including a focus on tumor-infiltrating lymphocytes (TIL).Experimental Design: We performed deep RNA-seq on pretreatment diagnostic tumors from 129 high-risk and 21 low- or intermediate-risk patients with neuroblastomas. We used single-sample gene set enrichment analysis to detect gene expression signatures of TILs in tumors and examined their association with clinical and molecular parameters, including patient outcome. The expression profiles of 190 additional pretreatment diagnostic neuroblastomas, a neuroblastoma tissue microarray, and T-cell receptor (TCR) sequencing were used to validate our findings.Results: We found that MYCN-not-amplified (MYCN-NA) tumors had significantly higher cytotoxic TIL signatures compared with MYCN-amplified (MYCN-A) tumors. A reported MYCN activation signature was significantly associated with poor outcome for high-risk patients with MYCN-NA tumors; however, a subgroup of these patients who had elevated activated natural killer (NK) cells, CD8+ T cells, and cytolytic signatures showed improved outcome and expansion of infiltrating TCR clones. Furthermore, we observed upregulation of immune exhaustion marker genes, indicating an immune-suppressive microenvironment in these neuroblastomas.Conclusions: This study provides evidence that RNA signatures of cytotoxic TIL are associated with the presence of activated NK/T cells and improved outcomes in high-risk neuroblastoma patients harboring MYCN-NA tumors. Our findings suggest that these high-risk patients with MYCN-NA neuroblastoma may benefit from additional immunotherapies incorporated into the current therapeutic strategies.

In order to access Controlled TARGET NBL data using the links below, users must submit an application for Authorized Access via dbGaP as described on dbGaP’s TARGET Study Page. To begin the application process, please view the information and instructions provided on the dbGaP Authorized Access Login Page under “dbGaP Data Download”.

Supplemental Data

• GDC Manifests
  • Controlled-Access Data Download Manifest (11 Files)
  • Open-Access Data Download Manifest (23 Files)
  • WGS CGI Files Download Manifest (137 Files)

• Copy Number Array
  • TARGET NBL Copy number array Level 1 Data (Controlled)
  • TARGET NBL Copy number array Level 2 Data (Controlled)
  • TARGET NBL Copy number array Level 3 Data
  • TARGET NBL Copy number array Design Information
  • TARGET NBL Copy number array Metadata
• Gene Expression Array
  • TARGET NBL Gene expression array Level 1 Data (Controlled)
  • TARGET NBL Gene expression array Level 2 Data (Controlled)
  • TARGET NBL Gene expression array Level 3 Data
  • TARGET NBL Gene expression array Metadata
• mRNA-Seq
  • TARGET NBL RNA-seq Level 3 data
  • TARGET NBL RNA-seq Level 3 data (Controlled)
  • TARGET NBL RNA-seq Metadata
• miRNA-Seq
  • TARGET NBL miRNA-seq Level 3 Data
  • TARGET NBL miRNA-seq Metadata
• Whole Exome Sequencing
  • TARGET NBL WXS Level 3 Data
  • TARGET NBL WXS Level 3 Data (Controlled)
  • TARGET NBL WXS Metadata
• Methylation Array
  • TARGET NBL Methylation array Level 1 Data (Controlled)
  • TARGET NBL Methylation array Level 2 Data
  • TARGET NBL Methylation array Level 3 Data
  • TARGET NBL Methylation array Metadata
• Whole Genome Sequencing
  • TARGET NBL WGS Level 3 Data
  • TARGET NBL WGS Level 3 Data (Controlled)
  • TARGET NBL WGS Level 4 Data
  • TARGET NBL WGS Metadata
• Targeted Capture Sequencing
  • TARGET NBL Targeted Capture Sequencing Level 3 Data
  • TARGET NBL Targeted Capture Sequencing Level 3 Data (Controlled)
  • TARGET NBL Targeted Capture Sequencing Design
  • TARGET NBL Targeted Capture Sequencing Metadata
• GWAS
  • TARGET NBL GWAS Level 2 Data (Controlled)
• Miscellaneous Files
  • TARGET NBL Sample Matrices
  • TARGET NBL ID Mapping Information
  • TARGET NBL CGI Requested Reports (Controlled)

Additional Resources

• OCG TARGET Data Matrix (link is external) Office of Cancer Genomics
• TARGET-NBL at SRA (link is external) NCBI

Instructions for Data Download

Open Access Data

1. Download the appropriate manifest file from the publication page
2. Use the manifest file to download data using the GDC Data Transfer Tool (DTT) or the GDC API
   • GDC DTT ( Download, User's Guide)
   • GDC API ( User’s Guide)

Controlled Access Data

1. Download the appropriate manifest file from the publication page
2. Download a token from the GDC Data Portal
   • GDC Data Portal ( Launch, User’s Guide)
3. Use the manifest file and token to download data using the GDC DTT or the GDC API
   • GDC DTT ( Download, User’s Guide)
   • GDC API ( User’s Guide)

For assistance, please contact the GDC Help Desk: support@nci-gdc.datacommons.io.